Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Management of Comorbid Medical Conditions in Schizophrenia

  • Chapter
  • First Online:
Schizophrenia

  • 4178 Accesses

Abstract

Patients with schizophrenia endure a markedly greater medical disease burden than the general population. In particular, cardiovascular and metabolic diseases are highly prevalent and lead to an increased overall mortality. The causes are multifactorial and include lifestyle factors (e.g., poor dietary habits), obstacles related to health care delivery, and the adverse effects of antipsychotic medications. The role of these various factors on the physical health of patients with schizophrenia and practical approaches to their management are discussed in this chapter, as well as the prevalence and management of non-cardiometabolic diseases, such as cancer and infectious diseases. The role of medication and the impact of these diseases on medication selection are discussed in more detail in Chap. 12.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med. 2006;21(11):1133–7.

    PubMed Central  PubMed  Google Scholar 

  2. Filik R, Sipos A, Kehoe PG, et al. The cardiovascular and respiratory health of people with schizophrenia. Acta Psychiatr Scand. 2006;113:298–305.

    CAS  PubMed  Google Scholar 

  3. Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry. 2013;170:324–33.

    PubMed  Google Scholar 

  4. Liao CC, Shen WW, Chang CC, Chang H, Chen TL. Surgical adverse outcomes in patients with schizophrenia: a population-based study. Ann Surg. 2013;257:433–8.

    PubMed  Google Scholar 

  5. Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizophr Bull. 1996;22(3):485–99.

    CAS  PubMed  Google Scholar 

  6. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–7.

    CAS  PubMed  Google Scholar 

  7. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004;192:19–27.

    PubMed  Google Scholar 

  8. Ran MS, Chen EYH, Conwell Y, et al. Mortality in people with schizophrenia in rural China: a 10-year cohort study. Br J Psychiatry. 2007;190:237–42.

    PubMed  Google Scholar 

  9. Fors BM, Isacson D, Bingefors K, Widerlov B. Mortality among persons with schizophrenia in Sweden: an epidemiological study. Nord J Psychiatry. 2007;61:252–9.

    PubMed  Google Scholar 

  10. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171(12):502–8.

    CAS  PubMed  Google Scholar 

  11. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173(7):11–53.

    CAS  PubMed  Google Scholar 

  12. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115–21.

    PubMed  Google Scholar 

  13. Rasanen S, Hakko H, Viilo K, Meyer-Rochow VB, Moring J. Avoidable mortality in long-stay psychiatric patients of Northern Finland. Nord J Psychiatry. 2005;59:103–8.

    PubMed  Google Scholar 

  14. Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res. 2003;117:127–35.

    PubMed  Google Scholar 

  15. Bradford DW, Kim MM, Braxton LE, Marx CE, Butterfield M, Elbogen EB. Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv. 2008;59:847–52.

    PubMed  Google Scholar 

  16. Cradock-O’Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv. 2002;53:874–8.

    PubMed  Google Scholar 

  17. Drapalski AL, Milford J, Goldberg RW, Brown CH, Dixon LB. Perceived barriers to medical care and mental health care among veterans with serious mental illness. Psychiatr Serv. 2008;59:921–4.

    PubMed  Google Scholar 

  18. Muir-Cochrane E. Medical co-morbidity risk factors and barriers to care for people with schizophrenia. J Psychiatr Ment Health Nurs. 2006;13(4):447–52.

    CAS  PubMed  Google Scholar 

  19. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 2000;283(4):506–11.

    CAS  PubMed  Google Scholar 

  20. Briskman I, Bar G, Boaz M, Shargorodsky M. Impact of co-morbid mental illness on the diagnosis and management of patients hospitalized for medical conditions in a general hospital. Int J Psychiatry Med. 2012;43(4):339–48.

    CAS  PubMed  Google Scholar 

  21. Nasrallah HA. Neurologic comorbidities in schizophrenia. J Clin Psychiatry. 2005;66 Suppl 6:34–46.

    PubMed  Google Scholar 

  22. Vahia IV, Diwan S, Bankole AO, et al. Adequacy of medical treatment among older persons with schizophrenia. Psychiatr Serv. 2008;59:853–9.

    PubMed  Google Scholar 

  23. Mitchell AJ, Lawrence D. Revascularization and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. Br J Psychiatry. 2011;198:424–41.

    Google Scholar 

  24. Whyte S, Penny C, Phelan M, Hippsley-Cox J, Majeed A. Clinical care and delivery quality of diabetes care in patients with schizophrenia and bipolar disorder: cross-sectional study. Diabet Med. 2007;24:1442–8.

    CAS  PubMed  Google Scholar 

  25. Folsom DP, McCahill M, Bartels SJ, Lindamer LA, Ganiats TG, Jeste DV. Medical comorbidity and receipt of medical care by older homeless people with schizophrenia or depression. Psychiatr Serv. 2002;53:1456–60.

    PubMed  Google Scholar 

  26. Martens PJ, Chochinov HM, Prior HJ, Fransoo R, Burland E; Need To Know Team. Are cervical cancer screening rates different for women with schizophrenia? A Manitoba population-based study. Schizophr Res. 2009;113(1):101–6.

  27. Daumit GL, Pronovost PJ, Anthony CB, Guallar E, Steinwachs DM, Ford DE. Adverse events during medical and surgical hospitalizations for persons with schizophrenia. Arch Gen Psychiatry. 2006;63:267–72.

    PubMed  Google Scholar 

  28. World Health Organization. High blood pressure-country experiences and effective interventions utilized across the European Region. WHO Regional Office for Europe. 2009:1–23. http://www.euro.who.int/__data/assets/pdf_file/0008/185903/e96816.pdf.Accessed31July 2013.

  29. Kilbourne AM, Morden NE, Austen K, et al. Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009;31(6):555–63.

    PubMed  Google Scholar 

  30. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86:15–22.

    PubMed  Google Scholar 

  31. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050–60.

    PubMed  Google Scholar 

  32. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101(1–3):295–303.

    PubMed  Google Scholar 

  33. Ferreira L, Belo A, Abreu-Lima C; RICAVA Study Group. A case-control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe. Rev Port Cardiol. 2010;29(10):1481–93.

    Google Scholar 

  34. Saddichha S, Vishnuvardhan G, Akhtar S. Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia. Int J Risk Saf Med. 2011;23(3):181–5.

    PubMed  Google Scholar 

  35. James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507–20.

    Google Scholar 

  36. Hsu JH, Chien IC, Lin CH, Chou YJ, Chou P. Hyperlipidemia in patients with schizophrenia: a national population-based study. Gen Hosp Psychiatry. 2012;34(4):360–7.

    PubMed  Google Scholar 

  37. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005;80(1):55–9.

    PubMed  Google Scholar 

  38. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58(12):1172–6.

    CAS  PubMed  Google Scholar 

  39. Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126:110–6.

    PubMed  Google Scholar 

  40. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med. 2007;24:481–5.

    CAS  PubMed  Google Scholar 

  41. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry. 2003;160:284–9.

    PubMed  Google Scholar 

  42. Sengupta S, Parrilla-Escobar MA, Klink RA, et al. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res. 2008;102:329–36.

    PubMed  Google Scholar 

  43. Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117(10):75–82.

    PubMed  Google Scholar 

  44. Curkendall SM, Mo J, Glasser DB, Stang RM, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004;65(5):715–20.

    PubMed  Google Scholar 

  45. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia. Schizophr Res. 2002;55(3):277–84.

    PubMed  Google Scholar 

  46. McCreadie RG on behalf of the Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534–9.

    Google Scholar 

  47. Henderson DC, Borba CP, Daley TB, et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry. 2006;18(2):99–105.

    PubMed  Google Scholar 

  48. Kato MM, Currier MB, Gomez CM, et al. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6:74–7.

    PubMed Central  PubMed  Google Scholar 

  49. Isomma B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9.

    Google Scholar 

  50. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96.

    CAS  PubMed  Google Scholar 

  51. Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1–3):103–10.

    PubMed  Google Scholar 

  52. Lieberman JA, Stroup S, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.

    CAS  PubMed  Google Scholar 

  53. Citrome LL, Holt RL, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother. 2007;41(10):1593–603.

    CAS  PubMed  Google Scholar 

  54. Tsai KY, Lee CC, Chou YM, Su CY, Chou FH. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr Res. 2012;138(1):41–7.

    PubMed  Google Scholar 

  55. Lin HC, Hsiao FH, Pfeiffer S, Hwang YT, Lee HC. An increased risk of stroke among young schizophrenia patients. Schizophr Res. 2008;101:234–41.

    PubMed  Google Scholar 

  56. Kang JH, Xirasagar S, Lin HC. Lower mortality among stroke patients with schizophrenia: a nationwide population-based study. Psychosom Med. 2011;73(1):106–11.

    PubMed  Google Scholar 

  57. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.

    Google Scholar 

  58. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009;32(6):1037–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–59.

    PubMed  Google Scholar 

  60. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595–600.

    CAS  PubMed  Google Scholar 

  61. Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:383–8.

    CAS  PubMed  Google Scholar 

  62. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166:391–9.

    CAS  Google Scholar 

  63. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69:1046–56.

    CAS  PubMed  Google Scholar 

  64. Wu R, Zhao J, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(1):185–93.

    CAS  PubMed  Google Scholar 

  65. Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012;169:813–21.

    PubMed  Google Scholar 

  66. Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012;138(1):54–7.

    PubMed  Google Scholar 

  67. Bjorkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299–305.

    PubMed  Google Scholar 

  68. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165:352–8.

    PubMed  Google Scholar 

  69. Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010;118(1–3):218–23.

    PubMed  Google Scholar 

  70. Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(3):211–7.

    CAS  PubMed  Google Scholar 

  71. Egger CM, Muehlbacher M, Schatz M, Nickel M. Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. J Clin Psychopharmacol. 2007;27(5):475–8.

    CAS  PubMed  Google Scholar 

  72. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28(4):169–75.

    Google Scholar 

  73. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101–7.

    PubMed  Google Scholar 

  74. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-psychopharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1–3):159–68.

    PubMed  Google Scholar 

  75. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91:31–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Rosenberg SD, Drake RE, Brunette RE, et al. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS. 2005;19:S26–33.

    PubMed  Google Scholar 

  77. De Hert M, Wampers M, van Eyck D, et al. Prevalence of HIV and hepatitis C infection among patients with schizophrenia. Schizophr Res. 2009;108(1–3):307–8.

    PubMed  Google Scholar 

  78. Blank MB, Mandell DS, Aiken L, Hadley TR. Co-occurrence of HIV and serious mental illness among Medicaid recipients. Psychiatr Serv. 2002;53(7):868–73.

    PubMed  Google Scholar 

  79. Nurutdinova D, Chrusciel T, Zeringue A, et al. Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans. AIDS. 2012;26(2):229–34.

    PubMed  Google Scholar 

  80. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry. 2003;160(1):172–4.

    PubMed  Google Scholar 

  81. Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Determining rates of hepatitis C in a clozapine treated cohort. Schizophr Res. 2010;124:86–90.

    PubMed  Google Scholar 

  82. Osher FG, Goldberg RW, McNary SW, et al. Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv. 2003;54(6):842–7.

    PubMed  Google Scholar 

  83. Nakamura Y, Koh M, Miyoski E, et al. High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. Prog Neuropsychopharmacol Biol Psychiatry. 2004;24:591–7.

    Google Scholar 

  84. Huckans MS, Blackwell AD, Harms TA, Hauser P. Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr Serv. 2006;57(3):403–6.

    PubMed  Google Scholar 

  85. Butterfield MI, Bosworth HB, Meador KG, et al. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatr Serv. 2003;54(3):848–53.

    PubMed  Google Scholar 

  86. Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics. 2007;48(5):405–11.

    PubMed  Google Scholar 

  87. Lok A, McMahon B. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    PubMed  Google Scholar 

  88. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm. Accessed 15 June 2013.

  89. Brunette MF, Drake RE, Marsh BJ, Torrey WC, Rosenberg SD; Five-Site Health and Risk Study Research Committee. Responding to blood-borne infections among persons with severe mental illness. Psychiatr Serv. 2003;54(6):860–5.

    Google Scholar 

  90. Rosenberg S, Brunette M, Oxman T, et al. The STIRR model of best practices for blood-borne diseases among clients with serious mental illness. Psychiatr Serv. 2010;55(6):660–4.

    Google Scholar 

  91. Johnson-Masotti AP, Pinkerton SD, Kelly JA, Stevenson LY. Cost-effectiveness of an HIV risk reduction intervention for adults with severe mental illness. AIDS Care. 2000;12(3):321–32.

    CAS  PubMed  Google Scholar 

  92. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010;36(1):165–72.

    PubMed Central  PubMed  Google Scholar 

  93. Huckans M, Mitchell A, Pavawalla S, et al. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. Antivir Ther. 2010;15(1):111–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  94. Chou FH, Tsai KY, Su CY, Lee CC. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res. 2011;129(2–3):97–103.

    PubMed  Google Scholar 

  95. Levav I, Lipshitz I, Novikov I, et al. Cancer risk among parents and siblings of patients with schizophrenia. Br J Psychiatry. 2007;190:156–61.

    CAS  PubMed  Google Scholar 

  96. Goldacre MJ, Kurina LM, Wotton CJ, Yeates D, Seagroat V. Schizophrenia and cancer: an epidemiological study. Br J Psychiatry. 2005;187:334–8.

    PubMed  Google Scholar 

  97. Hippisley-Cox J, Vinogradova Y, Coupland C, Parker C. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry. 2007;64(12):1368–76.

    PubMed  Google Scholar 

  98. McGinty EE, Zhang Y, Guallar E, et al. Cancer incidence in a sample of Maryland residents with serious mental illness. Psychiatr Serv. 2012;63(7):714–7.

    PubMed  Google Scholar 

  99. Catts SV, O’Toole BI, Frost AD. Cancer incidence in patients with schizophrenia and their first-degree relatives—a meta-analysis. Acta Psychiatr Scand. 2008;117(5):323–36.

    CAS  PubMed  Google Scholar 

  100. Lin CY, Lane HY, Chen TT, Wu YH, Cy W, Wu VY. Inverse association between cancer risks and age in schizophrenic patients; a 12-year nationwide cohort study. Inverse association between cancer risks and age in schizophrenic patients: a 12-year nationwide cohort study. Cancer Sci. 2013;104(3):383–90.

    CAS  PubMed  Google Scholar 

  101. Capasso RM, Lineberry TW, Bostwick JM, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: county, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98(1–3):287–94.

    PubMed  Google Scholar 

  102. Tran E, Rouillon F, Loze JY, et al. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer. 2009;115:3555–62.

    PubMed  Google Scholar 

  103. Levav I, Kohn R, Barchana M, et al. The risk for cancer among patients with schizoaffective disorders. J Affect Disord. 2009;114(1–3):316–20.

    PubMed  Google Scholar 

  104. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr Res. 2009;114(1–3):6–16.

    PubMed  Google Scholar 

  105. Seeman MV. Preventing breast cancer in women with schizophrenia. Acta Psychiatr Scand. 2011;123(2):107–17.

    CAS  PubMed  Google Scholar 

  106. Cole M, Padmanabhan A. Breast cancer treatment of women with schizophrenia and bipolar disorder from Philadelphia, PA: lessons learned and suggestions for improvement. J Cancer Educ. 2012;27(4):774–9.

    PubMed  Google Scholar 

  107. Sharma A, Ngan S, Nandoskar A, et al. Schizophrenia does not adversely affect the treatment of women with breast cancer: a cohort study. Breast. 2010;19(5):410–20.

    PubMed  Google Scholar 

  108. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 2001;58:573–8.

    CAS  PubMed  Google Scholar 

  109. Dalton SO, Schuz J, Engholm G, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: summary of findings. Eur J Cancer. 2008;44(14):2074–85.

    PubMed  Google Scholar 

  110. Mateen FJ, Jatoi A, Lineberry TW, et al. Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report. Psychooncology. 2008;17(7):721–5.

    PubMed Central  PubMed  Google Scholar 

  111. Howard LM, Barley EA, Davis E, et al. Cancer diagnosis in people with severe mental illness: practical and ethical issues. Lancet Oncol. 2010;11:797–804.

    PubMed  Google Scholar 

  112. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511–8.

    CAS  PubMed  Google Scholar 

  113. De Leon J, Diaz FJ. A meta-analysis of world-wide studies demonstrating an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.

    PubMed  Google Scholar 

  114. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance abuse in psychosis. Clin Psychol Rev. 2007;27:494–510.

    PubMed  Google Scholar 

  115. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res. 2001;48:109–23.

    CAS  PubMed  Google Scholar 

  116. McEvoy JP, Freudenrich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46:125–9.

    CAS  PubMed  Google Scholar 

  117. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychiatry. 2000;20:94–8.

    CAS  Google Scholar 

  118. Evins AD, Cather C, Culhane MA, et al. A 12-week double-blind placebo-controlled study of bupropion SR added to high dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27(4):380–6.

    CAS  PubMed  Google Scholar 

  119. Batki SL, Dimmock AJ, Wade M, et al. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict. 2007;16:253–9.

    PubMed  Google Scholar 

  120. Hsu JH, Chien IC, Lin CH, et al. Increased risk of chronic obstructive pulmonary disease in patients with schizophrenia: a population-based study. Psychosomatics. 2013;54(4):345–51.

    PubMed  Google Scholar 

  121. Copeland LA, Mortensen EM, Zeber JE, Pugh MJ, Restrepo MI, Dalack GW. Pulmonary disease among inpatient decedents: impact of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:720–6.

    PubMed  Google Scholar 

  122. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013;68(2):171–6.

    PubMed  Google Scholar 

  123. Pedersen MS, Benros ME, Agerbo E, Borglum AD, Mortensen PB. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. Schizophr Res. 2012;138(1):58–62.

    PubMed  Google Scholar 

  124. Chen YH, Lee HC, Lin HC. Prevalence and risk of atopic disorders among schizophrenia patients: a nationwide population based study. Schizophr Res. 2009;108(1–3):191–6.

    PubMed  Google Scholar 

  125. Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163(3):521–8.

    PubMed  Google Scholar 

  126. Kelly DL, Conley BB. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone or fluphenazine. J Clin Psychiatry. 2005;66(1):80–4.

    CAS  PubMed  Google Scholar 

  127. Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res. 1992;6(3):181–92.

    CAS  PubMed  Google Scholar 

  128. Allebeck P, Rodvall Y, Wistedt B. Incidence of rheumatoid arthritis among patients with schizophrenia, affective psychosis or neurosis. Acta Psychiatr Scand. 1985;71(6):615–9.

    CAS  PubMed  Google Scholar 

  129. Mors O, Mortensen PB, Ewald H. A population-based register study of the association between schizophrenia and rheumatoid arthritis. Schizophr Res. 1999;40(1):67–74.

    CAS  PubMed  Google Scholar 

  130. Oken RJ, Schulzer M. At issue: Schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull. 1999;25(4):625–38.

    CAS  PubMed  Google Scholar 

  131. Chang YT, Chen PC, Tsai IJ, et al. Bidirectional relation between schizophrenia and epilepsy: a population-based retrospective cohort study. Epilepsia. 2011;52(11):2036–42.

    PubMed  Google Scholar 

  132. Marsh L, Rao V. Psychiatric complications in patients with epilepsy: a review. Epilepsy Res. 2002;49(1):11–33.

    PubMed  Google Scholar 

  133. Adachi N, Onuma T, Nishiwaki S, et al. Inter-ictal and post-ictal psychoses in frontal lobe epilepsy: a retrospective comparison with psychoses in temporal lobe epilepsy. Seizure. 2000;9(5):328–35.

    CAS  PubMed  Google Scholar 

  134. Wotton CJ, Goldacre MJ. Coexistence of schizophrenia and epilepsy: record-linkage studies. Epilepsia. 2012;53:e71–4.

    PubMed  Google Scholar 

  135. Clarke MO, Tanskanen A, Huttunen MO, Clancy M, Cotter DR, Cannon M. Evidence for shared susceptibility to epilepsy and psychosis: a population-based family study. Biol Psychiatry. 2012;71(9):836–9.

    PubMed  Google Scholar 

  136. Marsh L, Sullivan EV, Morrell M, Lim KO, Pfefferbaum A. Structural brain abnormalities in patients with schizophrenia, epilepsy, and epilepsy with chronic interictal psychosis. Psychiatry Res. 2001;108(1):1–15.

    CAS  PubMed  Google Scholar 

  137. Cascella NG, Schretlen DJ, Sawa A. Schizophrenia and epilepsy: is there a shared susceptibility? Neurosci Res. 2009;63(4):227–35.

    PubMed Central  PubMed  Google Scholar 

  138. Beary M, Hodgson R, Wildgust HJ. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J Psychopharmacol. 2012;26(5 Suppl):52–61.

    PubMed  Google Scholar 

  139. Butler M, Lane RL, McApine D, et al. Integration of mental health/substance abuse and primary care. Evidence reports/technology assessments, No. 173. 2008. Agency for Healthcare Research and Quality U.S. Department of Health and Human Services. http://www.ahrq.gov/research/findings/evidence-based-reports/mhsapc-evidence-report.pdf Accessed 31 July 2013.

  140. Katon WJ, Lin EHB, Korff MV, et al. Collaborative care for patients with depression and chronic illness. N Engl J Med. 2010;363(27):2611–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  141. Druss BG, Rohrbaugh RM, Levinson CM, et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001;58(9):861–8.

    CAS  PubMed  Google Scholar 

  142. Rubin AS, Littenberg B, Ross R, Wehry S, Jones M. Effects on processes and costs of care associated with the addition of an internist to an inpatient psychiatry team. Psychiatr Serv. 2005;56(4):463–7.

    PubMed  Google Scholar 

  143. Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM. A randomized trial of medical care management for community mental health settings: the primary care access, referral, and evaluation (PCAARE) study. Am J Psychiatry. 2010;167:151–9.

    PubMed Central  PubMed  Google Scholar 

  144. Druss BG, von Esenwein SA. Improving general and medical care for persons with mental and addictive disorders; systematic review. Gen Hosp Psychiatry. 2006;28:145–53.

    PubMed  Google Scholar 

  145. Smith TE, Sederer LI. A new kind of homelessness for individuals with serious mental illness? The need for a “mental health home”. Psychiatr Serv. 2009;60:528–33.

    PubMed  Google Scholar 

  146. Scharf DM, Eberhart NK, Schmidt N, et al. Integrating primary care into community behavioral health settings: programs and early implementation experiences. Psychiatr Serv. 2013;64(7):660–5.

    PubMed  Google Scholar 

  147. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2013. Epub ahead of print. https://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.full.pdf. Accessed 17 March 2014.

  148. United States Preventive Service Task Force. www.uspreventiveservicestaskforce.org. Accessed 21 July 2013.

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Rush University Medical Center, Chicago, IL, 60612, USA

    Jeffrey T. Rado

  2. Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 60612, USA

    Jeffrey T. Rado

Authors
  1. Jeffrey T. Rado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey T. Rado .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, Rush University, Chicago, Illinois, USA

    Philip G. Janicak

  2. UCLA Semel Institute, Los Angeles, California, USA

    Stephen R. Marder

  3. College of Medicine, University of Florida, Gainesville, Florida, USA

    Rajiv Tandon

  4. Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, Illinois, USA

    Morris Goldman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rado, J.T. (2014). Management of Comorbid Medical Conditions in Schizophrenia. In: Janicak, P., Marder, S., Tandon, R., Goldman, M. (eds) Schizophrenia. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0656-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0656-7_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0655-0

  • Online ISBN: 978-1-4939-0656-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation